Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered serious bleeding events. Pharmaceutical firms, like the makers of Xarelto, have a duty to ensure that their drugs are reasonably secure for use - and failure to accomplish
so may possibly be grounds for compensation. Our lawyers are operating tough to obtain those hurt by the drug the compensation they are entitled to.
Whilst bleeding can be a common complication connected with anticoagulants, it has been alleged that Xarelto is far more unsafe than traditional blood thinners since no antidote exists to reverse its blood-thinning effects. This means that, inside the occasion of an emergency, sufferers might be at risk for irreversible bleeding difficulties, which includes life-threatening internal
and gastrointestinal hemorrhaging.
If you or a loved a single suffered a critical bleeding event soon after taking Xarelto, you may have legal recourse. For far more data, speak to us these days to have your case reviewed, totally free of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for previous and future medical bills, lost wages, pain and suffering and, in cases of death, funeral expenses. In addition, they may be searching for punitive damages, that are typically awarded to punish the defendant and deter other businesses from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is unsafe and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Since of this, the lawsuits claim, doctors have no effective indicates of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs in the lawsuits allege serious and fatal injuries, which includes cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user in the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding occasion.
Xarelto is linked to severe bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing dangerous clotting.Visit this page
for much more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.